Skip to content

MBX Biosciences, Inc. MBX Return on equity

Return on equity at other companies

Eli Lilly logo
Eli LillyLLY
107.6%+29.9pp
Amgen logo
AmgenAMGN
101.3%-4.4pp
Viking Therapeutics logo
Viking TherapeuticsVKTX
-70%-94.5pp
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-63.3%-12.2pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-61.4%-2.5pp
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-39.2%+14.5pp

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Calculated from MBX Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s return on equity?
MBX Biosciences, Inc. (MBX) reported return on equity of -25.7% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.